Can mupirocin prevent methicillin-resistant Staphylococcus aureus infections?

doi:10.1186/cc3720

Critical Care
Volume 9
Issue 3

Viewing options:

Abstract
Full text
PDF (37KB)

Associated material:

Related literature:

Articles citing this article
on Google Scholar
on ISI Web of Science
on PubMed Central
Other articles by authors
on Google Scholar

Wertheim HF
Vos MC

on PubMed

Wertheim HF
Vos MC
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Post to:

Commentary

Can mupirocin prevent methicillin-resistant Staphylococcus aureus infections?

Heiman FL Wertheim and Margreet C Vos

Erasmus MC, Department of Medical Microbiology and Infectious Disease, Rotterdam, The Netherlands

author email corresponding author email

Critical Care 2005, 9:257-258doi:10.1186/cc3720


Published:	5 May 2005

See related research article http://ccforum.com/content/9/3/R246

Abstract

In a retrospective study, Dr Muller and colleagues have assessed the efficacy of mupirocin nasal ointment alongside hygienic measures in methicillin-resistant Staphylococcus aureus (MRSA)-positive patients admitted to the intensive care unit (ICU). Their findings, which suggest that intranasal mupirocin can prevent ICU-related MRSA infections, need confirmation in a well-designed clinical trial. In general: early identification, isolation and treatment of all MRSA carriers, including health care workers, and disinfection of contaminated environments, are the main 'ingredients' of an effective MRSA 'search and destroy' program.